このアイテムのアクセス数: 152

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s12931-021-01877-8.pdf7.9 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorSuezawa, Takahiroen
dc.contributor.authorKanagaki, Shuheien
dc.contributor.authorKorogi, Yoheien
dc.contributor.authorNakao, Kazuhisaen
dc.contributor.authorHirai, Toyohiroen
dc.contributor.authorMurakami, Kojien
dc.contributor.authorHagiwara, Masatoshien
dc.contributor.authorGotoh, Shimpeien
dc.contributor.alternative末澤, 隆浩ja
dc.contributor.alternative金墻, 周平ja
dc.contributor.alternative興梠, 陽平ja
dc.contributor.alternative平井, 豊博ja
dc.contributor.alternative村上, 浩二ja
dc.contributor.alternative萩原, 正敏ja
dc.contributor.alternative後藤, 慎平ja
dc.date.accessioned2021-11-17T08:44:18Z-
dc.date.available2021-11-17T08:44:18Z-
dc.date.issued2021-
dc.identifier.urihttp://hdl.handle.net/2433/265948-
dc.descriptioniPS細胞を用いてヘルマンスキー・パドラック症候群の肺病態の解析に成功 --研究が困難な遺伝性疾患の治療薬開発の足がかりに--. 京都大学プレスリリース. 2021-11-15.ja
dc.description.abstract[Background] Somatic cells differentiated from patient-specific human induced pluripotent stem cells (iPSCs) could be a useful tool in human cell-based disease research. Hermansky–Pudlak syndrome (HPS) is an autosomal recessive genetic disorder characterized by oculocutaneous albinism and a platelet dysfunction. HPS patients often suffer from lethal HPS associated interstitial pneumonia (HPSIP). Lung transplantation has been the only treatment for HPSIP. Lysosome-related organelles are impaired in HPS, thereby disrupting alveolar type 2 (AT2) cells with lamellar bodies. HPSIP lungs are characterized by enlarged lamellar bodies. Despite species differences between human and mouse in HPSIP, most studies have been conducted in mice since culturing human AT2 cells is difficult. [Methods] We generated patient-specific iPSCs from patient-derived fibroblasts with the most common bi-allelic variant, c.1472_1487dup16, in HPS1 for modeling severe phenotypes of HPSIP. We then corrected the variant of patient-specific iPSCs using CRISPR-based microhomology-mediated end joining to obtain isogenic controls. The iPSCs were then differentiated into lung epithelial cells using two different lung organoid models, lung bud organoids (LBOs) and alveolar organoids (AOs), and explored the phenotypes contributing to the pathogenesis of HPSIP using transcriptomic and proteomic analyses. [Results] The LBOs derived from patient-specific iPSCs successfully recapitulated the abnormalities in morphology and size. Proteomic analysis of AOs involving iPSC-derived AT2 cells and primary lung fibroblasts revealed mitochondrial dysfunction in HPS1 patient-specific alveolar epithelial cells. Further, giant lamellar bodies were recapitulated in patient-specific AT2 cells. [Conclusions] The HPS1 patient-specific iPSCs and their gene-corrected counterparts generated in this study could be a new research tool for understanding the pathogenesis of HPSIP caused by HPS1 deficiency in humans.en
dc.language.isoeng-
dc.publisherBioMed Central (BMC)en
dc.publisherSpringer Natureen
dc.rights© The Author(s) 2021.en
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.en
dc.rightsThe Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.subjectHPS1en
dc.subjectPatient-specific iPSCsen
dc.subjectAlveolar epithelial type 2 cellsen
dc.subjectGiant lamellar bodyen
dc.titleModeling of lung phenotype of Hermansky–Pudlak syndrome type I using patient-specific iPSCsen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleRespiratory Researchen
dc.identifier.volume22-
dc.relation.doi10.1186/s12931-021-01877-8-
dc.textversionpublisher-
dc.identifier.artnum284-
dc.addressDepartment of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University; Watarase Research Center, Kyorin Pharmaceutical Co. Ltd.en
dc.addressWatarase Research Center, Kyorin Pharmaceutical Co. Ltd.en
dc.addressDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto Universityen
dc.addressWatarase Research Center, Kyorin Pharmaceutical Co. Ltd.en
dc.addressDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto Universityen
dc.addressWatarase Research Center, Kyorin Pharmaceutical Co. Ltd.en
dc.addressDepartment of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto Universityen
dc.identifier.pmid34736469-
dc.relation.urlhttps://www.kyoto-u.ac.jp/ja/research-news/2021-11-15-0-
dcterms.accessRightsopen access-
datacite.awardNumber15K21114-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K21114/-
dc.identifier.pissn1465-9921-
dc.identifier.eissn1465-993X-
jpcoar.funderName日本学術振興会ja
jpcoar.awardTitleヒトiPS細胞由来II型肺胞上皮細胞の量産化と遺伝性肺線維症の病態解析への応用ja
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons